---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-051421"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:27:49.344251+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics stockholders approve reverse stock split of up to 1-for-50

## Summary
- Shareholders approved reverse stock split at ratio between 1-for-15 and 1-for-50, ratio set by Board with Series A consent.
- Reverse stock split proposal received 24,984,901 votes for, 7,906,612 against, and 40,629 abstentions.
- Adjournment proposal approved with 27,928,931 votes for, 4,899,237 against, and 103,974 abstentions.

## SEC filing metadata
- accession: 0001213900-23-051421
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023051421/0001213900-23-051421-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023051421/ea180879-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-051421
- JSON: https://secwatch.observer/filing/0001213900-23-051421.json
- Plain text: https://secwatch.observer/filing/0001213900-23-051421.txt

## Key facts
- Shareholder Votes
  Allarity Therapeutics, Inc. shareholders approved To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal at the 2023-06-23 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Proposal 2 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (“Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 27,928,931 4,899,237 103,974 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023051421/0001213900-23-051421-index.htm
- Shareholder Votes
  Allarity Therapeutics, Inc. shareholders approved To approve an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-15 and 1-for-50 at the 2023-06-23 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-06-23
  source text: Proposal 1 : To approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix A, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.0001 per share, at a ratio between 1-for-15 and 1-for-50 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board, subject to the consent of the holder of Series A Preferred Stock (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 24,984,901 7,906,612 40,629 -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023051421/0001213900-23-051421-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.